Abstract
We describe the first reported case of a syndrome of inappropriate secretion of antidiuretic hormone (SIADH) induced by low-dose tacrolimus in a patient with autoimmune disease. A 41-year-old man with systemic lupus erythematosus (SLE) developed hyponatremia induced by SIADH after administration of tacrolimus (0.06 mg/kg per day). In this case, the hyponatremia promptly resolved upon withdrawal of tacrolimus. This case strongly suggests that SIADH is a potentially important complication of tacrolimus administration, irrespective of dosage, and should be borne in mind whenever the drug is used.
Similar content being viewed by others
References
Fleischmann R, Iqbal I, Stern RL. Tacrolimus in rheumatoid arthritis. Expert Opin Pharmacother. 2006;7:91–8.
Tanaka H, Oki E, Tsugawa K, Nonaka K, Suzuki K, Ito E. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study. Lupus. 2007;16:896–900.
Marchewka Z, Kuźniar J, Zynek-Litwin M, Falkiewicz K, Szymańska B, Roszkowska A, et al. Kidney graft function in long-term cyclosporine and tacrolimus treatment: comparative study with nephrotoxicity markers. Transpl Proc. 2009;41:1660–5.
Atkison P, Joubert G, Barron A, Grant D, Paradis K, Seidman E, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet. 1995;345:894–6.
Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int. 2000;13:313–26.
Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation. 1995;59:1606–13.
Maemori M, Hayashi T, Ikeda H, Obata T, Tsukuda H, Nishimura S, et al. Syndrome of inappropriate secretion of antidiuretic hormone induced by tacrolimus hydrate. Tumor Res. 2004;39:7–10.
Azuma T, Narumi H, Kojima K, Nawa Y, Hara M. Hyponatremia during administration of tacrolimus in an allogeneic bone marrow transplant recipient. Int J Hematol. 2003;78:268–9.
O’Regan S, Carson S, Chesney RW, Drummond KN. Electrolyte and acid-base disturbances in the management of leukemia. Blood. 1977;49:345–53.
Harper PG, Souhami RL, Spiro SG, Geddes DM, Guimaraes M, Fearon F, et al. Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy. Cancer Treat Rep. 1982;66:463–70.
Fabrice GK, Guy D. Inappropriate secretion of ADH and central diabetes insipidus are related to antiphospholipid antibodies in SLE—case report and review of the literature. Nephrol Dial Transpl. 2006;21:3311–5.
Uribe AG, Vila LM, McGwin G Jr, Sanchez ML, Reveille JD, Alarcon GS. The systemic lupus activity measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004;31:1934–40.
Honjoh H, Kobayashi S, Okada H, Ikeda T. Inappropriate secretion of antidiuretic hormone (SIADH) in a patient with pleurisy related to adult onset Still’s disease. Clin Nephrol. 1995;44:400–1.
Chan TY. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management. Drugs Aging. 1997;11:27–44.
Higgins R, Ramaiyan K, Dasgupta T, Kanji H, Fletcher S, Lam F, et al. Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrol Dial Transpl. 2004;19:444–50.
Sakamoto K, Yamada K, Arita S, Hamaguchi K, Kashiwabara H, Yokoyama T. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. Transpl Proc. 1995;27:826–8.
Heering P, Ivens K, Aker S, Grabensee B. Distal tubular acidosis induced by FK506. Clin Transpl. 1998;12:465–71.
Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E. A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer. 1979;44:896–8.
Winkler M, Christians U. A risk-benefit assessment of tacrolimus in transplantation. Drug Saf. 1995;12:348–57.
Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics. 2008;5:535–41.
Naniwa T, Watanabe M, Banno S, Maeda T. Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Rheumatol Int. 2009;29:1287–91.
Oki E, Tsugawa K, Suzuki K, Tanaka H. Effective treatment of a refractory case of systemic lupus erythematosus with low-dose tacrolimus (in Japanese). Nippon Jinzo Gakkai Shi. 2007;49:1020–4.
Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn’s disease: a single-center experience. Inflamm Bowel Dis. 2008;14:7–12.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Suemori, K., Hasegawa, H., Nanba, C. et al. Syndrome of inappropriate secretion of antidiuretic hormone induced by tacrolimus in a patient with systemic lupus erythematosus. Mod Rheumatol 21, 97–100 (2011). https://doi.org/10.1007/s10165-010-0350-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-010-0350-2